Alvogen Launches Generic Equivalent to Suboxone® (Buprenorphine/Naloxone) Sublingual Film

Pine Brook, New Jersey (ots/PRNewswire) - Global pharmaceutical
company, Alvogen, has launched its generic equivalent to Suboxone®
sublingual film (buprenorphine hydrochloride/naloxone hydrochloride)
in the U.S., which will be available in 2mg/0.5 mg, 4mg/1mg, 8
mg/2mg, and 12 mg/3mg strengths.

The launch took place, pursuant to a 31 January 2019 agreement
between Alvogen and Indivior, following the issuance of a mandate
from the U.S. Court of Appeals for the Federal Circuit vacating the
preliminary injunction that had previously been granted enjoining Dr.
Reddy's Laboratories from marketing its product.

Lisa Graver, President of Alvogen Americas, commented: "We are
excited to launch this important product that will empower patients
suffering from opioid dependence. The launch demonstrates a
significant commitment from our teams to bringing affordable generic
medicines to the market."

Suboxone sublingual film is indicated for treatment of opioid
dependence. U.S. sales for Suboxone were approximately $1.1 billion
in 2018, based on Indivior SEC Filings.

Alvogen currently has 75 products in development and pending FDA
approval for the U.S. market. Annual brand sales for filed products
and those under development have current brand sales exceeding $35
billion, according to IMS IQVIA (2018).

*Suboxone is a registered trademark of Indivior UK LLC.

Please click here (http://assets.ctfassets.net/13xgobmebls4/4GvsFj
buEqQ86WGkqpBxwC/c01b5d0ba5d96a56cda2aea9b23c1829/PI355-01_PL355-01_R
12-18_Bup_pr1.pdf) for full Prescribing Information including
Medication Guide.

About Alvogen

Alvogen is a global, privately owned pharmaceutical company
focused on developing, manufacturing and selling generic, brand,
over-the-counter medicines (OTC) and biosimilar products for patients
around the world. The company has commercial operations in 35
countries with 2,800 employees and operates four manufacturing and
development hubs in the U.S., Romania, Korea and Taiwan. North
America is Alvogen's single largest market and other key markets
include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine,
Japan and China.

Learn more about Alvogen on www.alvogen.com

Media Contact

Halldor Kristmannsson
Global Corporate Marketing & Communications
Tel: (+354) 522 2900
Email: halldor.kristmannsson@alvogen.com

ots Originaltext: Alvogen
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Alvogen, übermittelt durch news aktuell